Exendin-4 reverts behavioural and neurochemical dysfunction in a pre-motor rodent model of Parkinson's disease with noradrenergic deficit

British Journal of Pharmacology

Volumn 167, Issue 7, 2012, Pages 1467-1479

  Rampersaud, N ^a   Harkavyi, A ^a   Giordano, G ^a   Lever, R ^a   Whitton, J ^a   Whitton, P S ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

6 OHDA; DSP 4; exendin 4; force swim test; novel object recognition; Parkinson's disease; pre motor; sucrose preference

Indexed keywords

DOPAMINE; EXENDIN 4; NORADRENALIN; SUCROSE;

ANHEDONIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR DISORDER; CELL COUNT; CONTROLLED STUDY; CORPUS STRIATUM; DEPRESSION; DOPAMINE BRAIN LEVEL; DRUG EFFICACY; EXPERIMENTAL MODEL; FRONTAL CORTEX; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LOCUS CERULEUS; MALE; MICRODIALYSIS; NONHUMAN; NORADRENALIN BRAIN LEVEL; NORADRENERGIC SYSTEM; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; SUBSTANTIA NIGRA; VALIDITY;

ANIMALS; BEHAVIOR, ANIMAL; BENZYLAMINES; CEREBRUM; DISEASE MODELS, ANIMAL; DOPAMINE; MALE; NEUROPROTECTIVE AGENTS; NOREPINEPHRINE; OXIDOPAMINE; PARKINSON DISEASE; PEPTIDES; RATS; RATS, WISTAR; VENOMS;

EID: 84868638043     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2012.02100.x     Document Type: Article

References (66)

1. Arango V, Underwood MD, Pauler DK, Kass RE, Mann JJ, (1996). Differential age-related loss of pigmented locus coeruleus neurons in suicides, alcoholics, and alcoholic suicides. Alcohol Clin Exp Res 20: 1141-1147.
2. Archer T, Fredriksson A, (2006). Influence of noradrenaline denervation on MPTP-induced deficits in mice. J Neural Transm 113: 1119-1129.
3. Bambico FR, Nguyen NT, Gobbi G, (2009). Decline in serotonergic firing activity and desensitization of 5-HT1A autoreceptors after chronic unpredictable stress. Eur Neuropsychopharmacol 19: 215-228.
4. Benarroch EE, (2009). The locus ceruleus norepinephrine system: functional organization and potential clinical significance. Neurology 73: 1699-1704.
5. Bertilsson G, Patrone C, Zachrisson O, Andersson A, Dannaeus K, Heidrich J, et al,. (2008). Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson's disease. J Neurosci Res 86: 326-338.
6. Biggs CS, Pearce BR, Fowler LJ, Whitton PS, (1992). Regional effects of sodium valproate on extracellular concentrations of 5-hydroxytryptamine, dopamine, and their metabolites in the rat brain: an in vivo microdialysis study. J Neurochem 59: 1702-1708.
7. Bowenkamp KE, David D, Lapchak PL, Henry MA, Granholm AC, Hoffer BJ, et al,. (1996). 6-hydroxydopamine induces the loss of the dopaminergic phenotype in substantia nigra neurons of the rat. A possible mechanism for restoration of the nigrostriatal circuit mediated by glial cell line-derived neurotrophic factor. Exp Brain Res 111: 1-7.
8. Braak H, Del Tredici K, Rub U, De Vos RA, Jansen Steur EN, Braak E, (2003). Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24: 197-211.
9. Branchi I, D'andrea I, Armida M, Cassano T, Pezzola A, Potenza RL, et al,. (2008). Nonmotor symptoms in Parkinson's disease: investigating early-phase onset of behavioral dysfunction in the 6-hydroxydopamine-lesioned rat model. J Neurosci Res 86: 2050-2061.
10. Chan-Palay V, Asan E, (1989). Alterations in catecholamine neurons of the locus coeruleus in senile dementia of the Alzheimer type and in Parkinson's disease with and without dementia and depression. J Comp Neurol 287: 373-392.
11. Chaudhuri KR, Healy DG, Schapira AH, (2006). Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol 5: 235-245.
12. Chen X, Xu L, Radcliffe P, Sun B, Tank AW, (2008). Activation of tyrosine hydroxylase mRNA translation by cAMP in midbrain dopaminergic neurons. Mol Pharmacol 73: 1816-1828.
13. Cohen AD, Zigmond MJ, Smith AD, (2011). Effects of intrastriatal GDNF on the response of dopamine neurons to 6-hydroxydopamine: time course of protection and neurorestoration. Brain Res 1370: 80-88.
14. Cummings JL, Masterman DL, (1999). Depression in patients with Parkinson's disease. Int J Geriatr Psychiatry 14: 711-718.
15. Dauer W, Przedborski S, (2003). Parkinson's disease: mechanisms and models. Neuron 39: 889-909.
16. Decastro M, Nankova BB, Shah P, Patel P, Mally PV, Mishra R, et al,. (2005). Short chain fatty acids regulate tyrosine hydroxylase gene expression through a cAMP-dependent signaling pathway. Brain Res Mol Brain Res 142: 28-38.
17. Delaville C, Deurwaerdere PD, Benazzouz A, (2011). Noradrenaline and Parkinson's disease. Front Syst Neurosci 5: 1-12.
18. Du Y, Ma Z, Lin S, Dodel RC, Gao F, Bales KR, et al,. (2001). Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proc Natl Acad Sci U S A 98: 14669-14674.
19. Ennaceur A, Delacour J, (1988). A new one-trial test for neurobiological studies of memory in rats. 1: behavioral data. Behav Brain Res 31: 47-59.
20. Fan R, Li X, Gu X, Chan JC, Xu G, (2010). Exendin-4 protects pancreatic beta cells from human islet amyloid polypeptide-induced cell damage: potential involvement of AKT and mitochondria biogenesis. Diabetes Obes Metab 12: 815-824.
21. Fornai F, Bassi L, Torracca MT, Scalori V, Corsini GU, (1995). Norepinephrine loss exacerbates methamphetamine-induced striatal dopamine depletion in mice. Eur J Pharmacol 283: 99-102.
22. Frisina PG, Haroutunian V, Libow LS, (2009). The neuropathological basis for depression in Parkinson's disease. Parkinsonism Relat Disord 15: 144-148.
23. Gallwitz B, (2011). Glucagon-like peptide-1 analogues for type 2 diabetes mellitus: current and emerging agents. Drugs 71: 1675-1688.
24. Harkavyi A, Whitton PS, (2010). Glucagon-like peptide 1 receptor stimulation as a means of neuroprotection. Br J Pharmacol 159: 495-501.
25. Harkavyi A, Abuirmeileh A, Lever R, Kingsbury AE, Biggs CS, Whitton PS, (2008). Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease. J Neuroinflammation 5: 1-9.
26. Hornykiewicz O, (1963). [The tropical localization and content of noradrenalin and dopamine (3-hydroxytyramine) in the substantia nigra of normal persons and patients with Parkinson's disease.]. Wien Klin Wochenschr 75: 309-312.
27. Iravani MM, Leung CC, Sadeghian M, Haddon CO, Rose S, Jenner P, (2005). The acute and the long-term effects of nigral lipopolysaccharide administration on dopaminergic dysfunction and glial cell activation. Eur J Neurosci 22: 317-330.
28. Isacson R, Nielsen E, Dannaeus K, Bertilsson G, Patrone C, Zachrisson O, et al,. (2010). The glucagon-like peptide 1 receptor agonist exendin-4 improves reference memory performance and decreases immobility in the forced swim test. Eur J Pharmacol 650: 249-255.
29. Jardanhazi-Kurutz D, Kummer MP, Terwel D, Vogel K, Dyrks T, Thiele A, et al,. (2010). Induced LC degeneration in APP/PS1 transgenic mice accelerates early cerebral amyloidosis and cognitive deficits. Neurochem Int 57: 375-382.
30. de Lau LM, Breteler MM, (2006). Epidemiology of Parkinson's disease. Lancet Neurol 5: 525-535.
31. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). NC3Rs Reporting Guidelines Working Group. Br J Pharmacol 160: 1577-1579.
32. Kim S, Moon M, Park S, (2009). Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson's disease. J Endocrinol 202: 431-439.
33. Kim SY, Lee YJ, Kim H, Lee DW, Woo DC, Choi CB, et al,. (2010). Desipramine attenuates forced swim test-induced behavioral and neurochemical alterations in mice: an in vivo(1)H-MRS study at 9.4T. Brain Res 1348: 105-113.
34. Klimek V, Stockmeier C, Overholser J, Meltzer HY, Kalka S, Dilley G, et al,. (1997). Reduced levels of norepinephrine transporters in the locus coeruleus in major depression. J Neurosci 17: 8451-8458.
35. Lategan AJ, Marien MR, Colpaert FC, (1990). Effects of locus coeruleus lesions on the release of endogenous dopamine in the rat nucleus accumbens and caudate nucleus as determined by intracerebral microdialysis. Brain Res 523: 134-138.
36. Ledoux JE, (2000). Emotion circuits in the brain. Annu Rev Neurosci 23: 155-184.
37. Lees AJ, Hardy J, Revesz T, (2009). Parkinson's disease. Lancet 373: 2055-2066.
38. Li Y, Perry T, Kindy MS, Harvey BK, Tweedie D, Holloway HW, et al,. (2009). GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. Proc Natl Acad Sci U S A 106: 1285-1290.
39. Li Y, Chigurupati S, Holloway HW, Mughal M, Tweedie D, Bruestle DA, et al,. (2012). Exendin-4 ameliorates motor neuron degeneration in cellular and animal models of amyotrophic lateral sclerosis. Plos ONE 7: e32008.
40. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
41. Marie RM, Barre L, Rioux P, Allain P, Lechevalier B, Baron JC, (1995). PET imaging of neocortical monoaminergic terminals in Parkinson's disease. J Neural Transm Park Dis Dement Sect 9: 55-71.
42. Martin B, Golden E, Carlson OD, Pistell P, Zhou J, Kim W, et al,. (2009). Exendin-4 improves glycemic control, ameliorates brain and pancreatic pathologies, and extends survival in a mouse model of Huntington's disease. Diabetes 58: 318-328.
43. Mavridis M, Degryse AD, Lategan AJ, Marien MR, Colpaert FC, (1991). Effects of locus coeruleus lesions on Parkinsonian signs, striatal dopamine and substantia nigra cell loss after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in monkeys: a possible role for the locus coeruleus in the progression of Parkinson's disease. Neuroscience 41: 507-523.
44. Mayberg HS, Solomon DH, (1995). Depression in Parkinson's disease: a biochemical and organic viewpoint. Adv Neurol 65: 49-60.
45. Merchenthaler I, Lane M, Shughrue P, (1999). Distribution of pre-pro-glucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system. J Comp Neurol 403: 261-280.
46. Owen AM, (2004). Cognitive dysfunction in Parkinson's disease: the role of frontostriatal circuitry. Neuroscientist 10: 525-537.
47. Paxinos G, Watson C, (1982). The Rat Brain in Stereotaxic Coordinates. Academic Press: Sydney.
48. Perry T, Haughey NJ, Mattson MP, Egan JM, Greig NH, (2002). Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4. J Pharmacol Exp Ther 302: 881-888.
49. Piech-dumas KM, Best JA, Chen Y, Nagamoto-combs K, Osterhout CA, Tank AW, (2001). The cAMP responsive element and CREB partially mediate the response of the tyrosine hydroxylase gene to phorbol ester. J Neurochem 76: 1376-1385.
50. Porsolt RD, Anton G, Blavet N, Jalfre M, (1978). Behavioural despair in rats: a new model sensitive to antidepressant treatments. Eur J Pharmacol 47: 379-391.
51. Remy P, Doder M, Lees A, Turjanski N, Brooks D, (2005). Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain 128: 1314-1322.
52. Ressler KJ, Nemeroff CB, (1999). Role of norepinephrine in the pathophysiology and treatment of mood disorders. Biol Psychiatry 46: 1219-1233.
53. Rommelfanger KS, Weinshenker D, (2007). Norepinephrine: the redheaded stepchild of Parkinson's disease. Biochem Pharmacol 74: 177-190.
54. Roozendaal B, Castello NA, Vedana G, Barsegyan A, Mcgaugh JL, (2008). Noradrenergic activation of the basolateral amygdala modulates consolidation of object recognition memory. Neurobiol Learn Mem 90: 576-579.
55. Ross RA, Reis DJ, (1974). Effects of lesions of locus coeruleus on regional distribution of dopamine-beta-hydroxylase activity in rat brain. Brain Res 73: 161-166.
56. Sachs C, Jonsson G, (1975). Mechanisms of action of 6-hydroxydopamine. Biochem Pharmacol 24: 1-8.
57. Schrag A, (2004). Psychiatric aspects of Parkinson's disease-an update. J Neurol 251: 795-804.
58. Shiba M, Bower JH, Maraganore DM, Mcdonnell SK, Peterson BJ, Ahlskog JE, et al,. (2000). Anxiety disorders and depressive disorders preceding Parkinson's disease: a case-control study. Mov Disord 15: 669-677.
59. Srinivasan J, Schmidt WJ, (2003). Potentiation of Parkinsonian symptoms by depletion of locus coeruleus noradrenaline in 6-hydroxydopamine-induced partial degeneration of substantia nigra in rats. Eur J Neurosci 17: 2586-2592.
60. Tadaiesky MT, Dombrowski PA, Figueiredo CP, Cargnin-Ferreira E, Da Cunha C, Takahashi RN, (2008). Emotional, cognitive and neurochemical alterations in a premotor stage model of Parkinson's disease. Neuroscience 156: 830-840.
61. Tolosa E, Compta Y, Gaig C, (2007). The premotor phase of Parkinson's disease. Parkinsonism Relat Disord 13 (Suppl): S2-S7.
62. Wang SH, Zhang ZJ, Guo YJ, Zhou H, Teng GJ, Chen BA, (2009). Anhedonia and activity deficits in rats: impact of post-stroke depression. J Psychopharmacol 23: 295-304.
63. Wang Y, Zhang QJ, Liu J, Ali U, Gui ZH, Hui YP, et al,. (2010). Noradrenergic lesion of the locus coeruleus increases apomorphine-induced circling behavior and the firing activity of substantia nigra pars reticulata neurons in a rat model of Parkinson's disease. Brain Res 1310: 189-199.
64. Winter C, Von Rumohr A, Mundt A, Petrus D, Klein J, Lee T, et al,. (2007). Lesions of dopaminergic neurons in the substantia nigra pars compacta and in the ventral tegmental area enhance depressive-like behavior in rats. Behav Brain Res 184: 133-141.
65. Zarow C, Lyness SA, Mortimer JA, Chui HC, (2003). Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. Arch Neurol 60: 337-341.
66. Ziemssen T, Reichmann H, (2007). Non-motor dysfunction in Parkinson's disease. Parkinsonism Relat Disord 13: 323-332.